Nature Biotechnology 2005 - Abstracts
| Nature Biotechnology 2005 | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| A bacterial one-hybrid system for determining the DNA-binding specificity of transcription factors. | Business | Michael H. Brodsky, Xiangdong Meng, Scot A. Wolfe | |||
| A classic assembly of nanobiomaterials. | Business | Brian Cook, Andreas Mershin, Liselotte Kaiser, Shugang Zhang | |||
| Activation of the mammalian immune system by siRNAs. | Business | Bryan R.G. Williams, Jean T. Marques | |||
| Addition diversity to plant transformation. | Business | Mary-Dell Chilton | |||
| Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. | Business | Bing Wang, Jian Zhang, Zhong Wang, Tong Zhu, Chunlian Chen, Chunping Qiao, Juan Li, Liqiao Zhou, Xiao Xiao | |||
| A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. | Business | Sarah Scaife, Peng Gong, Matthew J. Epton, Guoliang Fu, Alexandra Hiscox, Kersty C. Condon, George C. Condon, Neil I. Morrison, David W. Kelly, Tariq Dafa'alla, Paul G. Coleman, Luke Alphey | |||
| A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. | Business | Joseph Schlessinger, Michael V. Milburn, Gideon Bollag, Graeme L. Card, Daniel Fong, Dean R. Artis, Blasdel Landy, Bruce P. England, Chao Zhang, Yoshihisa Suzuki, Sam Gillette, Prabha N. Ibrahim, Sung-Hou Kim, Kam Y. J. Zhang | |||
| A farewell to bacterial ARMs?(antibiotic resistance markers) | Business | Philip A. Rea | |||
| A gut feeling. | Business | David A.F. Loebel, Patrick Tam P.L. | |||
| A high-throughput assay for assessing the cell permeability of combinatorial libraries. | Business | Thomas Kodadek, Peng Yu, Bo Lui | |||
| A human beta-cell line for transplantation therapy to control type 1 diabetes. | Business | Jonathan R.T. Lakey, Ji-Won Yoon, Philippe Leboulch, Hirofumi Noguchi, Teru Okitsu, Yong Chen, Michiki Narushima, Kohji Takei, Alejandro Soto Gutierrez, Naoya Kobayashi, Shuhei Nakaji, Noriaki Tanak, Jorge David Rivas-Carrillo, Kimiaki Tanaka, Nalu Navarro-Alvarez, Yoshihito Tanaka, Atsushi Miki, Hee-Sook Jun, Shun-Ai Li, Karen A. Westerman | |||
| A molecular ruler based on plasmon coupling of single gold and silver nanoparticles. | Business | A. Paul Alivisatos, Carsten Sonnichsen, Bjorn M. Reinhard, Jan Liphardt | |||
| An anopheles transgenic sexing strain for vertor control. | Business | Andrea Crisanti, Flamina Catteruccia, Jason P. Benton | |||
| An enriched look at tyrosine phosphorylation. | Business | Thomas P. Conrads, Timothy D. Veenstra | |||
| A new role for scientists in the biological weapons convention. | Business | Gigi Kwik Gronvall | |||
| A new school for screening. | Business | Harren Jhoti | |||
| Angel investors shy away from biotech. | Business | Aaron Bouchie | |||
| An individual approach. | Business | Ricki Lewis | |||
| An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. | Business | Steven P. Gygi, Daniel Schwartz | |||
| Antibodies. | Business | ||||
| Antibodies in the breakdown lane. | Business | Richard S. Blumberg, Wayne I. Lencer | |||
| Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. | Business | David B. Weiner, Judy Lieberman, Erwei Song, Premlata Shankar, Sang-Kyung Lee, Wayne A. Marasco, Derek M. Dykxhoorn, Pencheng Zhu, Fheng Yi, Deborah Pallliser, Dipanjan Chowdhury, Steven Kussman | |||
| Are the current ontologies in biology good ontologies? | Business | Larisa N. Soldatova, Ross D. King | |||
| A reverse genetic, nontransgenic approach to wheat crop improvement by TILLING.(targeting induced local lesions in genomes) | Business | Ann J. Slade, Susan I. Fuerstenberg, Dayna Loeffler, Michael N. Steine, Daniel Facciotti | |||
| Arming antibodies: Prospects and challenges for immunoconjugates. | Business | Anna M. Wu, Peter D. Senter | |||
| Artificial cell-cell communication in yeast saccharomyces cerevisiae using signaling elements from Arabidopsis thaliana. | Business | Ron Weiss, Ming-Tang Chen | |||
| A small molecule-kinase interaction map for clinical kinase inhibitors. | Business | David J. Lockhart, Todd A. Carter, Miles A. Fabian, William H. III Biggs, Daniel K. Treiber, Corey E. Atteridge, Mihai D. Azimioara, Zdravko V. Milanov, Darren E. Insko, Julia M. Ford, Michael G. Benedetti, Anne Marie Velasco, Michael A. Insko, Margaret Galvin, Lisa M. Wodicka, Andiliy G. Lai, Jay L. Gerlach, Pietro Ciceri, Hitesh K. Patel, Jean-Michael Lelias, Robert M. Grotzfeld, Patrick P. Zarrinkar, Shamal A. Mehta, Sanna Herrgard, Mark Flyod, Philip T. Edeen | |||
| Assessing computational tools for the discovery of transcription factor binding sites. | Business | George M. Church, Nan Li, Chun Ye, Martin Tompa, Eleazar Eskin, Alexander V. Favorov, Martin C. Frith, W. James Kent, Vsevolod J. Makeev, Andrei A. Mironov, William Stanford Noble, Giulio Pavesi, Graziano Pesole, Mireille Regnier, Nicolas Simonis, Saurabh Sinha, Gert Thijs, Jacques van Helden, Mathias Vandenbogaert, Timothy L. Bailey, Zhiping Weng, Christopher Workman, Zhou Zhu, Bart De Moor | |||
| A Turing-like test for biological modeling.(Alan Turing) | Business | David Harel | |||
| A two-for-one in tomato nutritional enhancement. | Business | Richard A. Dixon | |||
| Auspicious antigens. | Business | Jenny Bangham | |||
| Australian biotech suffers growing pains. | Business | Graeme O'Neill | |||
| Automatic generation of cellular reaction networks with Moleculizer 1.0. | Business | Roger Brent, Larry Lok | |||
| A very firm handshake: Biotech's growing negotiating power.(Industry Overview) | Business | Karl A. Thiel | |||
| Avimers hold their own. | Business | George Georgiou, Ki Jun Jeong, Robert Mabry | |||
| A window on the dynamics of biological switches. | Business | Michael Bittner | |||
| Bacterial lessons in sausage making. | Business | Lars Axelsson, Vincent G.H. Eijsink | |||
| Bacteria to the rescue. | Business | Rekha Seshadri, John Heidelberg | |||
| Baculovirus as versatile vectors for protein expression in insect and mammalian cells. | Business | Thomas A. Kost, J. Patrick Condreay, Donald L. Jarvis | |||
| Banking on red blood cells. | Business | Narla Mohandas | |||
| B cells lead the way in tumor progression. | Business | Kirsty Minton | |||
| Biocontrol genome deciphered. | Business | Dieter Haas | |||
| Biofilms strike back. | Business | Philip S. Stewart, George A. O'Toole | |||
| Biosynthetic labeling of RNA with uracil phosphoribosyltransferase allows cell-specific microarray analysis of mRNA synthesis and decay. | Business | John C. Boothroyd, Eric Jan, Michael D. Cleary, Christopher D. Meiering, Rebecca Guymon | |||
| Biotech's gender gap. | Business | Crispin Littlehales | |||
| Biotech venture capital-it's not too late to be early. | Business | Arthur Klausner | |||
| Boolean calculations made easy (for ribozymes). | Business | Adam A. Margolin, Milan N. Stojanovic | |||
| Breaking the barriers to global gene delivery. | Business | Matthew D. Weitzman, Patricia A. Thistlewaite | |||
| Bringing amyloid into focus.(Amyloid binding ligands ) | Business | Todd E. Golde, Brian J. Bacskai | |||
| Bringing safe and effective cell therapies to the bedside. | Business | Robert A. Preti | |||
| Building a strategy for maximizing intellectual property value. | Business | William A. Barrett | |||
| Building relationships with technology transfer officers.(relationship between inventors and TTP) | Business | Prem O. Das | |||
| Cat and mouse in regulating genetic 'enhancement'. | Business | Henry Miller | |||
| Cautious industry welcome for US flu vaccine plan. | Business | Jim Kling | |||
| Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. | Business | Ralph Weissleder, Lee Josephson, Kimberly Kelly, Eric Yi Sun, Timur Shtatland | |||
| Characterization and culture of human embryonic stem cells. | Business | Melissa K. Carpenter, Lisa M. Hoffman | |||
| Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. | Business | di Bernardo, Diego; Wojtovich, Andrew P., Thompson, Michael J.; Elliott, Sean J., Gardener, Timothy S.; Schaus, Scott E., Chobot, Sarah E.; Collins, James J., Erin L. Eastwood | |||
| China beckons to clinical trial sponsor. | Business | Hepeng Jia | |||
| China's biotech experiments. | Business | Jia Hepeng | |||
| China steps towards international M&A. | Business | Hepeng Jia | |||
| Chromatography data system.(Product/Service Evaluation) | Business | ||||
| Clone on the range: What animal biotech is bringing to the table. | Business | Alan Dove | |||
| Closing the circle of osmoregulation. | Business | Patrik D'haeseleer | |||
| Combinatoria polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes. | Business | David A. Hopwood, John R. Carney, Hugo G. Menzella, Ralph Reid, Sunil S. Chandran, Sarah J. Reisinger, Kedar G. Patel, Daiel V. Santi | |||
| Combined static and dynamic analysis for determining the quality of time-series expression profiles. | Business | Itamar Simon, Zahava Siegfried, Jason Ernst, Ziv Bar-Joseph | |||
| Complete genome sequence of the acetic acid bacterium gluconobacter oxydans. | Business | Armin Ehrenreich, Arnim Wiezer, Heiko Liesegang, Christina Prust, Marc Hoffmeister, Wolfgang Florian Fricke, Gehard Gottschalk, Uwe Deppenmeier | |||
| Complete genome sequence of the plant commensal Pseudomonas fluorescens Pf-5. | Business | Jacques Ravel, Joyce E. Loper, Ian T. Paulsen, Michelle L. Gwinn, Robert J. Dodson, Leland S. Pierson III, Linda S. Thomashow, Lauren M. Brinkac, Robert T. DeBoy, Sean C. Daugherty, Rekha Seshadri, Ramana Madupu, A. Scott Durkin, Qinghu Ren, Caroline M. Press, Donald Y. Kobayashi, Garry S. A. Myers, Dmitri V. Mavrodi, Stephen A. Sullivan, Mary J. Rosovitz, Liwei Zhou, Davd J. Schneider, Samuel W. Cartinhour, Wiliam C. Nelson, Janice Weidman, Kisha Watkins, Kevin Tran, Hoda Khouri, Elizabeth A. Pierson | |||
| Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes. | Business | Ronald R. Breaker, Robert Penchovsky | |||
| Construction of lycopene-overproducing E. coli strains by combining systematic and combinatorial gene knockout targets. | Business | Gregory Stephanopoulos, Hal Alper, Kohei Miyaoku | |||
| Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. | Business | Luigi Naldini, Mario Amendola, Mary Anna Venneri, Alessandra Biffi, Elisa Vigna | |||
| Customized human embryonic stem cells. | Business | George Q. Daley | |||
| Designing dendrimers for biological applications. | Business | Jean M.J. Frechet, Cameron C. Lee, John A. MacKay, Francis C. Szoka | |||
| Design of a genome-wide siRNA library using an artificial neural network. | Business | Jonathan Hall, Francois Natt, Dieter Huesken, Joerg Lange, Craig Mickanin, Jan Weiler, Fred Asselbergs, Justin Warner, Brian Meloon, Sharon Engel, Avi Rosenberg, Dalia Cohen, Mark Labow, Mischa Reinhardt | |||
| Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. | Business | Stefan H.E. Kaufmann, Volker Patzel, Sascha Rutz, Isabell Dietrich, Christian Koberle | |||
| Developing an intellectual property portfolio for the academic or not-for-profit institution. | Business | Coe A. Bloomberg | |||
| Dicing with siRNA. | Business | Bryan R.G. Williams | |||
| Directed evolution of human T-cell receptors with picomolar affinities by phage display. | Business | Jonathan M. Boulter, Yi Li; Baston, Emma, Ruth Moysey, Peter E. Molloy, Anne-Lise Vuidepot, Tara Mahon, Steven Dunn, Nathaniel Liddy, Jansen Jacob, Bent K. Jakobsen | |||
| Discovering DNA regulatory elements with bacteria. | Business | Martha L. Bulyk | |||
| Discovery of regulatory elements in vertebrates through comparative genomics. | Business | Martin Tompa, Amol Prakash | |||
| Early-stage exits: Sometimes less is more.(Venture Capitalist David Mack's history with Angiosyn) | Business | George S. Mack | |||
| Eco-friendly insect management. | Business | Ernst A. Wimmer | |||
| Effect of sampling on topology predictions of protein-protein interaction networks. | Business | Marc Vidal, Jing-Dong J. Han, Denis Dupuy, Nicolas Bertin, Michael E. Cusick | |||
| Efficient differentiation of human embryonic stem cells to definitive endoderm. | Business | Evert Kroon, Kevin A. D'Amour, Alan D. Agulnick, Susan Eliazer, Olivia G. Kelly, Emmanuel E. Baetge | |||
| Efficient gene silencing with high selectivity using mission shRNA lentiviral vectors. | Business | Henry George, Betsy Boedeker, Edward J. Weinstein, Dave Citter, Roger Chui, Andrea Spencer, Jenny Reade | |||
| Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. | Business | John F. Engelhardt, Jeffrey S. Chamberlain, Yi Lai, Yongping Yue, Mingju Liu, Arkasubhra Ghosh, Dongsheng Duan | |||
| Embryonic stem cells without embryos? | Business | Markus Grompe | |||
| Emergent behavior of growing knowledge about molecular interactions. | Business | Andrey Rzhetsky, Murat Cokol, Ivan Iossifov, Chani Weinreb | |||
| Empowering the inventor: The case of monoclonal antibodies. | Business | Mike Clark | |||
| Energy well spent on a prokaryotic genome. | Business | Brian McNeil, Linda Harvey | |||
| Engineered antibody fragments and the rise of single domains. | Business | Peter J. Hudson, Philipp Holliger | |||
| Engineering novel binding proteins from nonimmunoglobulin domains. | Business | Andreas Pluckthun, H. Kaspar Binz, Patrick Amstutz | |||
| Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. | Business | Carlos Vaccaro, Jinchun Zhou, Raimund J. Ober, E. Sally Ward | |||
| Engineering vascularized skeletal muscle tissue. | Business | Robert Langer, Patricia A. D'Amore, Shulamit Levenberg, Daniel S. Kohane, Jeroen Rouwkema, Mara Macdonald, Evan S. Garfein, Diane C. Darland, Robert Marini, Clemens A van Blitterswijk, Richard C. Mulligan | |||
| Engineering vascularized tissue. | Business | Rakesh K. Jain, Dai Fukumura, Patrick Au, Dan G. Duda, Josh Tam | |||
| Enrichment and analysis of peptide subsets using fluorous affinity tags and mass spectrometry. | Business | Ansgar Brock, Scott M. Brittain, Scott B. Ficarro, Eric C. Peters | |||
| Entrepreneurs: The missing link in the training of medical scientists. | Business | David A. Shaywitz | |||
| Enzyme family-specific and activity-based screening of chemical libraries using enzyme microarrays. | Business | Jun Miyake, Daniel P. Funeriu, Jorg Eppinger, Lucil Denizot, Masato Miyake | |||
| Erythroprotein in the UK: A setback for gene patents? | Business | R. Stephen Crespi | |||
| ESTs stumble at the utility threshold.(Expressed sequence tags) | Business | Paula K. Davis | |||
| Ethanol fermentation on the move. | Business | Thomas W. Jeffries | |||
| Evolutionary optimization of fluorescent proteins for intracellular FRET.(Forster resonance energy transfer) | Business | Annalee W. Nguyen, Patrick S. Daugherty | |||
| Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus. | Business | Timo K. Korhonen, Katariina Majander, Lena Anton, Jenni Antikainen, Hannu Lang, Mirko Brummer, Benita Westerlund-Wilkstrom | |||
| Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. | Business | Marie-Catherine Giarratana, Therese Cynober, Ladan Kobari, Michael C. Marden, Helene Lapilonne, Henri Wajcman, David Chalmers, Douay; Luc, Laurent Kiger | |||
| Flexibility: The guiding principle for antibody manufacturing. | Business | Keith L. Carson | |||
| From XML to RDF: How semantic web technologies will change the design of 'omic' standards. | Business | Jonas S. Almeida, Xiaoshu Wang, Robert Gorlitsky | |||
| Fruit-specific RNAi-mediated suppression of DET1 enhances carotenoid and flavonoid content in tomatoes. | Business | Paul D. Fraser, Peter M. Bramley, Chris Bowler, Ganga Rao Davuluri, Ageeth van Tuinen, Alessandro Manfredonia, Robert Newman, Diane Burgess, David A. Brummell, Stephan R. King, John Uhlig, Joe Palys, Henk M.J. Pennings | |||
| Functional annotation and network reconstruction through cross-platform integration of microarray data. | Business | Michael Primig, Xianghong Jasmine Zhou, Angela Wong, Oscar M. Aparicio, Caleb E. Finch, Ming-Chih J. K, Juan Nunez- Iglesias, Todd E. Morgan, Wing Hung Wong | |||
| Functional genome annotation through phylogenomic mapping. | Business | Balji S. Srinivasan, Farah Tengra, Nora B. Caberoy, Barry S. Goldman, Garret Suen, Anthony G. Garza, Rion G. Taylor, Roy D. Welch, Radhika Shah | |||
| Gene cloning. | Business | ||||
| Gene discovery by ribozyme and siRNA libraries. | Business | Kazunari Taira, Hideo Akashi, Sahohime Matsumoto | |||
| Gene knockdown by large circular antisense for high-throughput functional genomics. | Business | Yun-Han Lee, Bin Hur, Kil-Hwan Han, Koo-Jeong Kang, Yong-Joo Kim, Seok-Yong Uhm, Jeong-Hoh Park, Ik-Jae Moon, Jong-Wook Park, Young-Bae Seu, Young-Ho Kim, Jong-Gu Park | |||
| Generation of functional ion-channel tools by E3 targeting. | Business | Jing Li, Ming Lei, Shang-Zhong Xu, Fanning Zeng, David J. Beech, Asipu Sivaprasadarao, Bin Gao, Chenliang Xiong | |||
| Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. | Business | Andrew E. Nixon, Rene Michael Hoet, Edward H. Cohen, Rachel Baribault Kent, Kristin Rookey, Sonia Schoonbroodt, Robert Charles Ladner, Mieke Steukers, Simon E. Hufton, Rob van Hegelsom, Shannon Hogan, Mailini Vishwanathan, Lili Huang, Nicole Coolen-van Neer, Louise Rem, Irina Kashin, Horacio G. Nastri, Nicolas Frans, Daniel Sexton, Mary Devlin, Issac J. Rondon, Marc Daukandt, Hennie R. Hoogenboom, Guannan Kuang, Jennifer A. Leeds, Henk Pieters | |||
| Gene targeting using zinc finger nucleases. | Business | Matthew H. Porteus, Dana Carroll | |||
| Gene therapy: Cursed or inching towards credibility. | Business | Malorye A. Branca | |||
| Genetically enhanced cows resist intramammary Staphylococcus aureus infection. | Business | Robert J. Wall, Anne M. Powell, Max J. Paape, David E. Kerr, Douglas D. Bannerman, Vernon G. Pursel, Kevin D. Wells, Neil Talbot, Harold W Hawk | |||
| Genome sequence of the chlorinated compound-respiring bacterium Dehalococcoides species strain CBDB1. | Business | Stephen H. Zinder, Lorenz Adrian, Richard Reinhardt, Michael Kube, Alfred Beck, Heiner Kuhl | |||
| German biotech sector inches forward despite long odds. | Business | Cormac Sheridon | |||
| Getting real about valuations in biotech. | Business | Ralph Villiger, Boris Bogdan | |||
| GlaxoSmithKline cancer drug threatens Herceptin market. | Business | Emily Waltz | |||
| GM rice forges ahead in China amid concerns over illegal planting.(genetically modified rice crops) | Business | Xun Zi | |||
| Golden opportunities. | Business | Paul Smaglik | |||
| Golden Rice gets a boost from maize: A more nutritious version of golden rice may offer a practical solution to vitamin A deficiency. | Business | Michael A. Grusak | |||
| Green light for mosquito control. | Business | Peter W. Atkinson | |||
| Guidelines for human embryonic stem cell research. | Business | Richard O. Hynes, Jonathan D. Moreno | |||
| Haplotyping in biomedicine--practical challenges.(Editorial) | Business | Charles R. Cantor, Matthew R. Nelson | |||
| High-throughput generation of small antibacterial peptides with improved activity. | Business | Robert E.W. Hancock, Kai Hilpert, Rudolf Volkmer-Engert, Tess Walter | |||
| Hot spot MRI emerges from the background.(magnetic resonance imaging) | Business | Jeff W.M. Bulte | |||
| How does gene expression clustering work? | Business | Patrik D'haeseleer | |||
| How to conduct competitive intelligence in your biotech startup. | Business | David Finegold, Salvador Carlucci, Anthony Page | |||
| Human antibodies from transgenic animals. | Business | Nils Lonberg | |||
| Identification of post-translational modifications by blind search of mass spectra. | Business | Dekel Tsur, Stephen Tanner, Ebrahim Zandi, Vineet Bafna, Pavel A. Pevzner | |||
| Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. | Business | Roberto D. Polakiewicz, Hui Zhang, John Rush, Erik J. Spek, Albrecht Moritz, Zha Xiang-Ming, Kimberly A. Lee, Ailan Guo, Michael J. Comb, Valerie L. Goss | |||
| Immunosuppressive networks in the tumor environment and their therapeutic relevance. | Business | Weiping Zou | |||
| Immunotherapy and chemotherapy: A practical partnership. | Business | Bruce W.S. Robinson, Richard A. Lake | |||
| Immunotherapy for pancreatic cancer: Science driving clinical progress. | Business | Dan Laheru, Elizabeth M. Jaffee | |||
| Improving the efficiency of RNA interference in mammals. | Business | Vivek Mittal | |||
| Improving the nutritional value of Golden Rice through increased pro-vitamin A contentPaine. | Business | Jacqueline A. Paine, Catherine A. Shipton, Sunandha Chaggar, Rhian M. Howells, Mike J. Kennedy, Gareth Vernon, Susan Y. Wright, Edward Hinchliffe, Jessica L. Adams, Aron L. Silverstone, Rachel Drake | |||
| Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. | Business | Shin-Ichi Nishikawa, Masahiro Yasunaga, Shinksuke Tada, Mitsuhiro Okada, Satomi Torikai-Nishiwaka, Lars Martin Jakt, Takumi Era, Yoko Nakano | |||
| Infrared spectroscopic imaging for histopathologic recognition. | Business | Stephen M. Hewitt, Daniel C. Fernandez, Rohit Bhargava, Ira W. Levin | |||
| Innovation and intellectual property rights in systems biology. | Business | Minna Allarakhia, Anthony Wensley | |||
| Insect resistance management in GM crops: Past, present and future.(genetically modified crops) | Business | Jian-Zhou Zhao, Richard T. Roush, Anthony M. Shelton, Sarah L. Bates | |||
| Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. | Business | K. Dane Wittrup, Douglas A. Lauffenburger, Balaji M. Rao | |||
| Integrative model of the response of yeast to osmotic shock. | Business | Stefan Hohmann, Edda Klipp, Bodil Nordlander, Roland Kruger, Peter Gennemark | |||
| Intein-based biosynthetic incorporation of unlabeled protein tags into isotopically labeled proteins for NMR studies. | Business | Sara Zuger, Hideo Iwai | |||
| Interaction maps for kinase inhibitors. | Business | James D. Griffin | |||
| Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. | Business | Stephen H. Leppla, Shihui Lui, Thomas H. Bugge, Vivien Redeye, Jeffrey G. Kuremsky, Marissa Kuhnen, Alfredo Molinolo | |||
| International patent law--boon or bane of biotech? | Business | Paroma Basu | |||
| In vivo detection of amyloid-beta deposits by near infrared imaging using an oxazine-derivative probe. | Business | Markus Rudin, Markus Stoeckli, Martin Hintersteiner, Albert Enz, Anne-Lise Jaton, Peter Frey, Willy Kinzy, Ulf Neumann, Rainer Kneuer, Matthias Staufenbiel, Karl-Heinz Wiederhold, Hans-Ulrich Gremlich | |||
| In vivo imaging platform for tracking immunotherapeutic cells. | Business | Hongyan Xu, Eric T. Ahrens, Rafael Flores, Penelope A. Morel | |||
| In vivo veritas. | Business | Thomas Tursz, Laurence Zitvogel | |||
| Islets for all? | Business | Christopher B. Newgard, Hans E. Hohmeier | |||
| It takes a village to grow a tissue. | Business | Randall T. Moon, David L. Kaplan, Gordana Vunjak-Novakovic | |||
| Japan-China merger puts growth in East Asia first.(GNI merged with Shanghai Genomics ) | Business | Doug Sipp | |||
| Japanese giants renew interest in industrial biotech. | Business | Doug Sipp | |||
| Lament of the really crummy deal. | Business | John Ritter, Robert MacWright, Pamela L. Cox, Jeff Skinner | |||
| Leaders and laggards in the stem cell enterprise. | Business | Stephen Herrera | |||
| Let us join together in silence.(transcriptional gene silencing) | Business | Katrin Bussell | |||
| Life, diversity and the pursuit of haplotypes. | Business | Jeanette McCarthy | |||
| Lisa Drakeman. | Business | Laura DeFrancesco | |||
| Looking and listening to light: The evolution of whole-body photonic imaging. | Business | Ralph Weissleder, Vasilis Ntziachristos, Jorge Ripoll, Lihong V. Wang | |||
| 'Magic' scissors for genome surgery. | Business | Karthikeyan Kandavelou, Mala Mani, Sundar Durai, Srinivasan Chandrasegaran | |||
| Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. | Business | Gosse J. Adema, Carl G. Figdor, Tom W.J. Scheenen, Jeff W.M. Bulte, I. Jolana M. de Vries, W. Joost Lesterhuis, Jelle O. Barentsz, Pauline Verdijk, J. Han van Krieken, Otto C. Boerman, Wim J.G. Oyen, Johannes J. Bonenkamp, Jan B. Boezeman, Cornelis J.A. Punt, Heerschap; Arend | |||
| Making it in the biotech business. | Business | Virginia Gewin | |||
| Malaysia tiptoes on the heels of Asian neighbors. | Business | Ichiko Fuyuno | |||
| Mammalian cell-based optimization of the biarsenical-binding tetracysteine motif for improved fluorescence and affinity. | Business | Roger Y. Tsien, Ben N.G. Giepmans, Brent R. Martin, Stephen R. Adams | |||
| Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome. | Business | Peter F. Stadler, Ivo L. Hofacker, Stefan Washietl, Alexander Huttenhofer | |||
| Material transfer agreements: Open science vs. proprietary claims. | Business | Victor Rodriguez | |||
| Mexico launches bold genome project. | Business | Stephan Herrera, Veronica Guerrero Mothelet | |||
| Microfabricated arrays of femtoliter chambers allow single molecule enzymology. | Business | Hiroyuki Noji, Yannick Rondelez, Shoji Takeuchi, Guillaume Tresset, Kazuhito V. Tabata, Hideyuki Arata, Hiroyuki Fujita | |||
| Microfluidic sorting of mammalian cells by optical force switching. | Business | Mark M. Wang, Norbert Hagen, Philippe J. Marchand, William F. Butler, Eugene Tu, Bob Dees, Daniel E. Raymond, Elinore M. Mercer, Joon Mo Yang, Anita H. Forster, Haichuan Zhang, Ilona Kariv | |||
| Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. | Business | Michel Sadelain, Lorenz Studer, Viviane Tabar, Edward D. Greenberg, Georgia Panagiotakos, Bill K. Chan, Philip H. Gutin | |||
| Mind the (biomedical funding) gap. | Business | Arthur Klausner | |||
| Minimum information requested in the annotation of biochemical models (MIRIAM). | Business | Barry L. Wanner, Pedro Mendes, Edda Klipp, Nicolas Le Novere, Fabien Campagne, Matt Halstead, Herbert Sauro, Hugh D. Spence, Andrew Finney, Michael Hucka, Upinder S. Bhalla, Julio Collado-Vides, Edmund J. Crampin, Poul Nielsen, Bruce Shapiro, Jacky L. Snoep | |||
| Monoclonal antibody successes in the clinic. | Business | Janice M. Reichert, Clark J. Rosenweig, Laura B. Faden, Matthew C. Dewitz | |||
| Monoclonal antibody therapy of cancer. | Business | Gregory P. Adams, Louis M. Weiner | |||
| Multi-kinase inhibitors create buzz at ASCO.(American Society of Clinical Oncology) | Business | Malorye A. Branca | |||
| Multiplexed detection of pathogen DNA with DNA-based fluorescence nanobarcodes. | Business | Yougen Li, Yen Thi Hong Cu, Dan Luo | |||
| Multiplexed electrical detection of cancer markers with nanowire sensor arrays. | Business | Charles M. Lieber, Fernando Patolsky, Gengfeng Zheng, Yi Cui, Wayne U. Wang | |||
| Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. | Business | Kevin W. Moore, Joshua Silverman, Peng Li, Richard Smith, Qiang Lu, Alberto Rivas, Joost Kolkman, Alice Bakker, Wayne To, Amy Duguay, Ben M. Alba, Erik Whitehorn, Candace Swimmer, Willem Pim C. Stemmer, Hon Le | |||
| Navigating an ethical patchwork-human gene banks. | Business | Karen J. Maschke | |||
| New apoptosis drugs face critical test. | Business | Ken Garber, Ann Arbor | |||
| New in mass!: On target with new technology.(AccuTOF, 4000 Ion Trap GC/MS, Surveyor MSQ Plus) | Business | ||||
| New sources of pancreatic beta-cells. | Business | Susan Bonner-Weir, Gordon C. Weir | |||
| 'Omic diagnostics trip up on way to clinic. | Business | Maloyre A. Branca | |||
| Overcoming obviousness when patenting nanotechnology inventions. | Business | Jeremy M. Stipkala | |||
| Overexpression of an Arabidopsis thaliana ABC transporter confers kanamycin resistance to transgenic plants. | Business | Ayalew Mentewab, C. Neal Stewart Jr. | |||
| Overhauling oversight: European drug legislation. | Business | Lincoln Tsang | |||
| Patent pools and standard setting in diagnostic genetics. | Business | Ted J. Ebersole, Marvin C. Guthrie, Jorge A. Goldstein | |||
| Peptide leads new class of chronic pain drug. | Business | Ken Garber, Ann Arbor | |||
| Pessimistic response to FDA leadership change. | Business | Jim Kling | |||
| Plasmon coupling measures up. | Business | Chad A. Mirkin, C. Shad Thaxton | |||
| Plug-and-play with RNA. | Business | James J. Collins, Farren J. Issacs | |||
| Poorer nations turn to publicly developed GM crops.(genetically modified crops) | Business | Joel I. Cohen | |||
| Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.(hepatitis B virus) | Business | David V. Morrissey, Jennifer A. Lockridge, Lucinda Shaw, Karin Blanchard, Kristi Jensen, Wendy Breen, Kimberly Hartsough, Lynn Machemer, Susan Radka, Vasant Jadhav, Narendra Vaish, Shawn Zinnen, Chandra Vargeese, Keith Bowman, Chris S. Shaffer, Lloyd B. Jeffs, Adam Judge, Ian MacLachlan, Barry Polisky | |||
| Probabilistic model of the human protein-protein interaction network. | Business | Akhilesh Pandey, Debashis Ghosh, Sooryanarayana Varambally, Arul M. Chinnaiyan, Daniel R. Rhodes, Scott A. Tomlins, Vasudeva Mahavisno, Terrence Barrette, Shanker Kalyana-Sundaram | |||
| Production of human monoclonal antibody in eggs of chimeric chickens. | Business | Babette S. Heyer, Philip A. Leighton, Zivko L. Nikolov, Lei Zhu, Marie-Cecile van de Lavior, Jenny Albanese, David O. Beenhouwer, Pina M. Cardarelli, Severino Cuison, David F. Deng, Jennifer H. Diamond, Lynae Green, Shrikant Deshpande, Edward L. Halk, Robert M. Kay, Allyn Kerchner, Christine M. Mather, Sherie L. Morrisson, David B. Passmore, Alicia Pradas-Monne, Benjamin T. Preston, Susan Wong, Vangipuram S. Rangan, Mingxia Shi, Mohan Srinivasan, Steven G. White, Peggy Winters-Digiacinto, Wen Zhou, Robert J. Etches | |||
| Programmable ligand-controlled riboregulators of eukaryotic gene expression. | Business | Christina D. Smolke, Travis S. Bayer | |||
| Protein tagging and detection with engineered self-assembling fragments of green fluorescent protein. | Business | Geoffrey S. Waldo, Stephanie Cabantous, Thomas C. Terwilliger | |||
| Proteomics takes stem cell analyses to another level. | Business | Andre Levchenko | |||
| Protozoan genomics for drug discovery. | Business | Kshitiz Chaudhary, David S. Roos | |||
| Public biotechnology 2004- the numbers. | Business | Riku Lahteenmaki, Stacy Lawrence | |||
| Quantitative mouse brain proteomics using culture-derived isotope tags as internal standards. | Business | Takeshi Nagasu, Yasushi Ishihama, Toshitaka Sato, Tsuyoshi Tabata, Norimasa Miyamoto, Koji Sagane, Yoshiya Oda | |||
| Rapid generation of specific antibodies by enhanced homologous recombination. | Business | Shunichi Takeda, Takehiko Shibata, Hidetaka Seo, Kunihiro Ohta, Mieko Masuoka, Hiromu Murofushi | |||
| Rapid-response vaccines: Does DNA offer a solution? | Business | Garet M. Forde | |||
| Receptor-targeted siRNAs. | Business | John J. Rossi | |||
| Reexamining the research exemption. | Business | Mauricio A. Flores, Cathryn Campbell | |||
| Regenerating the heart. | Business | Michael A. Laflamme, Charles E. Murry | |||
| Regulating transgenic crops sensibly: Lessons from plant breeding, biotechnology and genomics. | Business | Kent J. Bradford, Allen Van Deynze, Neal Gutterson, Wayne Parrott, Steven H. Strauss | |||
| Rescue and propagation of fully retargeted oncolytic measles viruses. | Business | Kah-Whye Peng, Mary Harvey, Takafumi Nakamura, Suzanne Greiner, Ian A. J. Lorimer, Charles D. James, Stephen J. Russell | |||
| Reverse engineering gene regulatory networks. | Business | Alexander J. Hartemink | |||
| RISC assessment. | Business | Arianne Heinrichs | |||
| RNAi-mediated pathways in the nucleus. | Business | James A. Birchler, Marjori A. Matzke | |||
| Scaling the biobusiness information mountain. | Business | Gary Walsh, Gwilym Williams | |||
| Selecting and screening recombinant antibody libraries. | Business | Hennie R. Hoogenboom | |||
| Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. | Business | Ian MacLachlan, Adam D. Judge, Vandana Sood, Janet R. Shaw, Dianne Fang, Kevin McClintock | |||
| Serum of youth? | Business | Hans-Willem Snoeck | |||
| Serum proteomics profiling- a young technology begins to mature. | Business | Jianhua Hu, Kevin R. Coombes, Jeffrey S. Morris, Sarah R. Edmonson, Keith A. Baggerly | |||
| Shortening the treatment of tuberculosis. | Business | Denis A. Mitchison | |||
| Should we make a fuss? A case for social responsibility in science. | Business | Jon Beckwith, Franklin Huang | |||
| Silencing the sceptics. | Business | Daniel Jones | |||
| Simple recipe for blocking ion channels. | Business | Christopher D. Benham | |||
| siRNA becomes smart and intelligent. | Business | Kazunari Taira, Makoto Miyagishi | |||
| siRNAs: Application in functional genomics and potential as therapeutics. | Business | Thomas Tuschl, Yair Dorsett | |||
| Sorting out metagenomes. | Business | Jo Handelsman | |||
| Space: The final frontier. | Business | James J. Medenbach | |||
| Specification of motoneurons from human embryonic stem cells. | Business | Xue-Jun Li, Zhong-Wei Du, Matthew Pankratz, Lauren O. Hansen, Ewa D. Zarnowska | |||
| Stable antibody expression at therapeutic level using the 2A peptide. | Business | Saili Yi, Jianmin Fang, Jing-Jing Qian, Thomas C. Harding, Guang Huan Tu, Melinda VanRoey, Karin Jooss | |||
| Stem and progenitor cell-based therapy of the human central nervous system. | Business | Steve Goldman | |||
| Stem cells-a hard sell to investors. | Business | Lutz B. Giebel | |||
| Stepwise engineering to produce high yields of very long-chain polyunsaturated fatty acids in plants. | Business | Guohai Wu, Martin Truksa, Nagamani Datla, Patricia Vrinten, Joerg Bauer, Thorsten Zank, Petra Cirpus, Ernst Heinz, Xiao Qui | |||
| Substrate-induced gene-expression screening of environmental metagenome libraries for isolation of catabolic genes. | Business | Takashi Abe, Kazuya Watanabe, Taku Uchiyama, Toshimichi Ikemura | |||
| Summary recommendations for standardization and reporting of metabolic analyses. | Business | Richard D. Beger, Erik Johansson, Manfred Spraul, Elaine Holmes, Ian D. Wilson, Jeremy K. Nicholson, John C. Lindon, Nigel Hardy, Hector C. Keun, Andrew Craig, Jake T.M. Pearce, Stephen J. Bruce, Susanna-Assunta Sansone, Henrik Antti, Par Jonsson, Clare Daykin, Mahendra Navarange, Elwin R. Verhej, Alexander Amberg, Dorrit Baunsgaard, Frans van der Ouderaa, Robert Plumb, Hartmut Schaefer, Glenn H. Cantor, Lois Lehman-McKeemann, Mark Earll, Svante Wold, John N. Haselden, Kerstin Kramer, Craig Thomas, Johann Lindberg, Ina Schuppe-Koistein, Michael D. Reily, Donald G. Robertson, Hans Senn, Arno Krotzky, Sunil Kochhar, Jonathan Powell | |||
| Survey reveals US university licensing up, startup formation down. | Business | Aaron Bouchie | |||
| Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. | Business | M.P. Lutolf, J. A. Hubell | |||
| Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. | Business | John J. Rossi, Dong-Ho Kim, Mark A. Behlke, Scott D. Rose, Mi-Sook Chang, Sangdun Choi | |||
| Synthetic shRNAs as potent RNAi triggers. | Business | Gregory J. Hannon, Wei Ge, Peter S. Linsley, Despina Siolas, Cara Lerner, Julja Burchard, Patrick J. Paddison, Michele A. Cleary | |||
| Systematic interpretation of genetic interactions using protein networks. | Business | Trey Ideker, Ryan Kelley | |||
| Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. | Business | Sylvestre Marillonnet, Carola Thoeringer, Romy Kandzia, Victor Klimyuk, Yuri Gleba | |||
| Tackling mastitis in diary cows. | Business | Pascal Rainard | |||
| Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. | Business | Michael J. Evans, Alan Saghatelian, Erik J. Sorensen, Benjamin F. Cravatt | |||
| The best preparation for a scientist job search. | Business | Grace H.W. Wong | |||
| The challenge to patent law of pure chemical protein synthesis. | Business | Aaron Xavier Fellmeth | |||
| The coming US patent opposition. | Business | Ted Apple | |||
| The complete genome sequence of the meat-borne lactic acid bacterium lactobacillus sakei 23K. | Business | Monique Zagorec, Stephane Chaillou, Marie-Christine Champomier-Verges, Monique ornet, Sophie Beaufils, Anne-Marie Crutz-Le COq, Anne-Marie Dudez, Veronique Martin, Emmanuelle Darbon-Rongere, Robert Bossy, Valentin Loux | |||
| The first 100 days: A biotech CEO survey. | Business | Nicolas Hollanders | |||
| The gatekeepers of hES cell products.(human embryonic stem) | Business | Sander Rabin | |||
| The genome sequence of the ethanologenic bacterium Zymomonas mobilis ZM4. | Business | Kye Joon Lee, Jeong-Sun Seo, Jae Joon Kim, Cheol Ju Park, Hyen Sam Kang, Hyonyong Chong, Jin Han Hong, Hyun-Myung Oh, Jung-Soon Lee, Su-Jung Jin, Hyun Seok Park, Hyungtae Kim, Hye-Won Um, Hee-Jong Lee, Kyoung-Oh Yoon, Jeong-Hyun Kim, Soo-Jin Oh, Cholhee Jung, Joon-Il Kil, Jae Young Kim, Hyung Lyun Kang, Se Yong Lee | |||
| The Human Cancer Genome Project-one more misstep in the war on cancer. | Business | George L. Gabor Miklos | |||
| The importance of angels in starting a US biotech venture. | Business | Jeffrey Sohl | |||
| The International Stem Cell Initiative: Toward benchmarks for human embryonic stem cell research. | Business | Ron McKay, Janet Rossant, Glyn N. Stacey, Martin F. Pera, Peter W. Andrews, Nissim Benvenisty, Henrik Semb | |||
| The Lego-ization of polyketide biosynthesis. | Business | David H. Sherman | |||
| The new fundamentalism. | Business | Dick Taverne | |||
| The patentability of antibodies in the United States. | Business | Thomas J. Kowalski, Deborah L. Lu, Angela M. Collison | |||
| The patentatibility of medicinal inventions related to personalized medicine in Japan. | Business | Itsuki Shimbo, Koichi Sumikura, Andrew Cobden | |||
| The promise of cancer vaccines. | Business | Eli Gilboa | |||
| Therapeutic antibody gene transfer. | Business | Wayne A. Marasco | |||
| The rise of venture capital and biotechnology in the US and Europe. | Business | Mark D. Dibner, Douglas P. Lee | |||
| The role of competitive intelligence in biotech startups. | Business | David Finegold, Salvador Carlucci, Anthony Page | |||
| The search for a sequencing thoroughbred. | Business | Jim Kling | |||
| Thinking ahead for effective clinical trials. | Business | Faiz Kermani, Catherine Narayan-Dubois | |||
| Thiol modifications in a snapshot. | Business | James Bardwell | |||
| Tobacco money reinvested in biotech. | Business | Myrna E. Watanabe | |||
| Toward a universal multistrain bacterial vaccine. | Business | Robert G. Feldman | |||
| Toward data standards for proteomics. | Business | Ram D. Sriram, Veeraswamy Ravichandran | |||
| Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. | Business | Hideyuki Okano, Satoshi Ogawa, Shinsuke Yuasa, Tomofumi Tanaka, Masayoshi Kinoshita, Shin-ichi Fukami, Uichi Koshimizu, Yuji Itabashi, Keijiro Sugimura, Fumiyuki Hattori, Takuya Shimazaki, Keiichi Fukuda | |||
| Tunable antibodies. | Business | Paul Carter, Louis M. Weiner | |||
| UK seeks to relax shareholder preemption rights. | Business | Peter Vermij | |||
| US biotechnology companies and foreign nationals: The changing dynamics of access to H-1B visas. | Business | A. Stephen Dahms, Stephen C. Trow | |||
| Using process diagrams for the graphical representation of biological networks. | Business | Akira Funahashi, Hiroaki Kitano, Kanae Oda, Yukiko Matsuoka | |||
| Viral-mediated plant transformation gets a boost. | Business | Stanton B. Gelvin | |||
| Virtual reality: The promise and pitfalls of going virtual. | Business | Hal Broderson | |||
| When a long shot is worth a shot.(Northfield Laboratories develops PolyHeme ) | Business | Tom Jacobs, Jeff Fischer | |||
| Whose tissue is it anyway? | Business | Jasper Bovenberg | |||
| Why tissue engineering needs process engineering. | Business | David J. Williams, Richard Archer | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.